INTERVIEW: Green Cross Thinks Global With Plasma Products, Vaccines
This article was originally published in PharmAsia News
Executive Summary
Green Cross Holdings’ president sat down recently with PharmAsia News and talked about the South Korean pharma group's business plans for the year ahead and the need for the government to step up its efforts to help the industry grow into the country's new growth engine in a shifting environment.
You may also be interested in...
US Approval Delay For Green Cross But Long Term Strategy Intact
Green Cross has hit a bump in its journey to commercialize an immunoglobulin product in the US, but analysts say the approval delay will not be a significant obstacle to its longer term North American strategy.
Trump Victory To Breathe Life Into Korean Biopharmas?
South Korean analysts and pharma firms are generally viewing Donald Trump's win in the US presidential election as positive for the sector, which is stepping up efforts to enter global markets including the US.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.